Overview and management of Colds and Flu

Abstract

The common cold is a viral infection that requires symptomatic treatment. It is usually self-limiting. Influenza is often referred to as the flu. There are several differences between the common cold and the flu, including the onset of the condition as influenza is typically more acute in onset and more debilitating. Treatment of both these conditions requires a symptomatic approach that should be evidence-based, including herbal remedies, over-the-counter medicines, antiviral agents and analgesics for pain and fever. This will be
discussed in more detail in the ensuing section.

Full text

2014 Vol 81 No 6S Afr Pharm J 19
ReView
Introduction
Every year, adults dread the winter months, especially because
they don’t want to “catch a cold”. The common cold is not so
uncommon, and adults experience a cold 2-4 times annually.
What causes colds and why do we get infected so easily? The
rhinovirus, coronavirus and the adenoviruses are responsible for
this self-limiting upper respiratory tract infection.
These viruses
spread very easily and quickly, especially through close proximity
to infected persons via hand-to-hand contact, or by inhalation of
airborne droplets through sneezing or coughing.
1
Once the virus has invaded the nasal cavity and bronchial epithelia,
it causes damage to the ciliated cells, which, in turn, release
inammatory mediators and cause inammation of the nose tissue
lining. Oedema is the result of the increased permeability of the
capillary cell walls. This eect is experienced as nasal congestion
and sneezing by the infected person. A postnasal drip, which is the
nasal mucous uid running down the throat, may also be present,
and can spread the virus and cause a sore throat and cough.
2
The cold should easily resolve with symptomatic treatment within
7-10 days, but sometimes it can be complicated by a bacterial
infection.
1
Symptoms include a sore throat, a stuy nose, sneezing,
mild to moderate fever (38.9°C), minor headaches, muscle aches
and coughing. Nasal discharge is normally clear and runny, and
may become thick and turn a yellow colour after a few days.
3
Inuenza, also known as the u, is a viral illness with high rates of
mortality and hospitalisation in persons aged 65 years and older.
4
People often confuse u with a common cold. However, there
are subtle dierences between the two. Inuenza occurs
especially between the months of December to March, but can
also take place at any time of the year. People all over the world
are apprehensive about acquiring u because they immediately
think of “swine” or “bird u”, and fear that they may die. Inuenza
epidemics can become very serious, and even fatal, when a new
strain evolves.
3
A u virus also spreads quickly through direct contact with infected
persons, or through close contact with infected persons who are
sneezing or coughing. The virus spreads from one day before
the onset of symptoms in healthy people and usually continues
to spread for ve days after the symptoms have developed, but
patients who are immunocompromised can shed the virus for
weeks to months.
3
The u virus manifests in dierent strains. The virus is a cluster of
genes connected together in a protein membrane, and covered
with glycoprotein molecules. The dierent u strains develop
according to the number of membranes of which they consist,
and also the type of glycoprotein that is present.
3
Refer to Table
I for an overview of the dierent inuenza strains with regard to
severity and who may become infected.
Table I: Dierences between the two inuenza strains with regard to
severity and who may become infected
3
Influenza strain Who will get
infected?
Severity
Inuenza A Animals and humans Causes major pandemics
Inuenza B Only humans Less common and less severe
than inuenza A
People who are infected with inuenza have distinctly dierent
symptoms to those with a common cold. The u virus has a rapid
onset, with fever, headaches, myalgia, malaise, a non-productive
Overview and management
of colds and flu
Natalie Schellack, BCur, BPharm, PhD(Pharmacy), Senior Lecturer
Quinten Labuschagne, BPharm, Academic Intern
Department of Pharmacy, Faculty of Health Sciences, University of Limpopo (Medunsa Campus)
Correspondence to: Natalie Schellack, e-mail: natalie.schellack@ul.ac.za
Keywords: common cold, u, over-the-counter medicines, decongestants, antiviral agents, u vaccine
Abstract
The common cold is a viral infection that requires symptomatic treatment. It is usually self-limiting. Inuenza is often referred to as the
u. There are several dierences between the common cold and the u, including the onset of the condition as inuenza is typically
more acute in onset and more debilitating. Treatment of both these conditions requires a symptomatic approach that should be
evidence-based, including herbal remedies, over-the-counter medicines, antiviral agents and analgesics for pain and fever. This will be
discussed in more detail in the ensuing section.
© Medpharm S Afr Pharm J 2014;81(6):19-26

2014 Vol 81 No 6S Afr Pharm J 20
ReView
cough, a sore throat and rhinitis. Flu symptoms resolve within
4-5 days, but the coughing and malaise may persist for 14 days or
longer.
3
Refer to Table II for a checklist of symptoms to be used to
dierentiate between a common cold and the u.
Table II: Checklist of symptoms to dierentiate between a cold
and the u
2,4
Symptoms Cold Flu
Fever Mild to moderate
(38.9°C)
Moderate to high
(38.9-40°C)
Headaches 7 3
General aches and pains 7 3
Fatigue, exhaustion and weakness 7 3
A stuy nose 3 3
Sneezing 3 3
A sore throat 3 3
Chest discomfort and coughing 3 3
Postnasal drip 3 3
Management of the common cold and flu
Pharmacotherapy is directed at alleviating associated symptoms.
Antibiotics are often prescribed erroneously, and in the absence
of a secondary bacterial infection. Antibiotics should only be
administered when a bacterial infection has been identied as a
pathogen, and should not be used as a preventative measure.
The following measures can be used to either prevent or
treat the symptoms of a common cold and u. (Each of these
recommendations will be discussed separately):
1,3,5
• A u vaccine is recommended by the Centers of Disease
Control and Prevention as a preventative measure against the
acquisition of the inuenza virus
• Combinations of active ingredients, e.g. decongestants, cough
suppressants and paracetamol, are available for use as over-the-
counter (OTC) products
• Drinkingplentyofuids: Water has been shown to be the best
uid with which to lubricate the mucous membranes
• Vitamins and minerals, e.g. vitamin C and zinc sulphate
• Antiviral drugs, e.g. neuraminidase inhibitors (zanamivir and
oseltamivir)
• Antiviral drugs, e.g. N-methyl D-aspartate receptor antagonists
(amantadine and rimantadine)
• Other [orally inhaled anticholinergics, inhaled corticosteroids,
herbal solutions and nonsteroidal anti-inammatory drugs
(NSAIDs)].
Vitamins and minerals
Evidence supporting the use of high dosages of vitamin C to
reduce the severity of the disease is lacking and inconclusive.
3,6
The
prophylactic use of vitamin C has only been shown to produce a
marked reduction in the risk of developing a cold or u in dened
populations, e.g. athletes, with a reduction of approximately 6% in
the disease duration.
3,7
High dosages of vitamin C also provide the following challenges:
• Intestinal and urinary problems, with a higher tendency to
develop headaches
• Vitamin C enhances the absorption of iron, and patients
with certain blood disorders, such as haemochromatosis,
thalassaemia or sideroblastic anaemia, should avoid high
dosages
• High dosages of vitamin C may also interfere with anticoagulant
medication, and blood tests used in diabetes and stool tests.
Zinc may inhibit viral growth, and could possibly reduce the
duration of cold symptoms. However, not enough high-quality
trials support the routine and high dosage use of zinc in preventing
a cold or u. Some reports have been lodged with the US Food and
Drug Administration (FDA) that nasal preparations containing zinc
may cause loss of smell.
3,6
Zinc may also reduce the absorption of
certain antibiotics. Food containing calcium and phosphorus can
impair the absorption of zinc.
Hydration for the common cold and flu
Contradictory literature exists for the recommendation of
hydration for the common cold and u. Some studies have
suggested that providing extra uid to a patient with an acute
respiratory condition may cause hyponatraemia and uid
overload, because of the release of the antidiuretic hormone. This
hormone is released in adults and children with lower respiratory
tract infections. The combination of increased production of the
antidiuretic hormone and extra uid may lead to hyponatraemia
and uid overload.
8
It has not been as clearly illustrated in upper
respiratory tract infections, and extra uid (water still remains
the rst choice) may help to lubricate the membranes in these
patients.
3,6
Other strategies used to treat the common cold and flu
Anticholinergic agents, such as inhaled ipratropium bromide,
may be used to treat a cough caused by the common cold. Nasal
preparations have shown some ecacy in reducing rhinorrhoea
and sneezing. Inhaled corticosteroids can be used to reduce the
swelling and inammation of the nasal mucosa, but have not
been shown to provide any benet in patients diagnosed with a
“common cold”.
9
There has been conicting evidence on the use of nasal irrigations
with hypertonic saline or a nasal wash. Some studies have shown
that nasal preparations that contain benzalkonium chloride as a
preservative may worsen symptoms and infections. Traditional
nasal washes that do not contain baking soda may be used
(plentiful uid and minimal salt) to remove mucus from the nose.
6,9
Medication used to alleviate the pain and fever associated with
the common cold and u includes aspirin, ibuprofen, naproxen
or paracetamol.
Aspirin should only be used in adults, and not in
children, as there is a risk of the latter acquiring Reye’s syndrome;
especially in children with a viral infection.
6,9

2014 Vol 81 No 6S Afr Pharm J 22
ReView
The use of codeine or hydrocodone as a cough suppressant is not
supported by the literature, and has been demonstrated to be no
more eective than placebo.
3,6,9
Herbal products and supplements include substances like
Echinacea, Chinese herbal cold and allergy products, elderberry
extracts, Andrographis paniculata, Pelargonium sidoides and
Acanthopanaxsenticosus.Supplements that contain these agents
are not formally regulated by the Medicines Control Council of
South Africa or even the FDA. Thus, these products are sold by
manufacturers without the permission of regulating authorities.
The following should be noted with regard to these products:
3,6,9
• Echinacea: There is no solid evidence that this product can
be used to treat or prevent a common cold. Some people are
allergic to Echinacea and develop a skin reaction called erythema
nodosum which features tender, red nodules under the skin
• Chinese herbal cold and allergy medication can be harmful, and
can cause renal damage and cancer as it may contain aristolochic
acid. Other herbal remedies imported from Asia sometimes
contain other pharmaceutical drugs, such as phenacetin and
steroids (with toxic metals), and should not be used
• Small studies have shown some ecacy in the use of elderberry
extract, with a shortened duration of u symptoms. This needs
to be conrmed by larger studies
• Pelargonium sidoides has been shown toreduce the duration
of 10 dierent cold symptoms in the literature, and may be of
some benet. This holds true for Andrographispaniculatatoo.
Flu vaccine and the influenza vaccine
Vaccines administered during autumn contain an inactive virus,
thus designed to provoke an immune response to the antigen
found on the surfaces of the viruses. Antigenic drift can occur in the
viruses, causing resistance to the vaccine. It is for this reason that
recommendations are based on the World Health Organization-
accredited regional laboratories, and changes are made every
year.
3,7
This is also the reason why the vaccine that is released in
September every year in the Northern Hemisphere is not exactly
the same as that released in February in the Southern Hemisphere.
Antibodies usually develop within two weeks of the vaccine being
administered. A peak in immunity occurs 4-6 after vaccination,
which then gradually wanes. Immunisation reduces the likelihood
of the u developing in healthy adults by approximately 70-90%.
3
If u has already developed in one family member in the household
and is accurately diagnosed, vaccination in the other members of
the household within 36-48 hours provides eective protection.
3
Table III provides an overview of people for whom vaccination
against the inuenza virus is a priority.
The vaccine is best administered in April, but can be given
throughout the winter months. Some adverse eects that may be
experienced include allergic reactions in people who are allergic
to eggs, soreness at the injection site, and u-like symptoms which
develop within 2-24 hours of the vaccination being administered
as a response to the virus proteins in the vaccine.
3,7
Individuals with
allergies to egg or chicken protein should not receive vaccines
that are produced via egg-based culturing techniques.
3,7
Combination products
Cough suppressants (also referred to as antitussive
agents)
The fact that the coughing reex fulls an important protective
function should always be kept in mind when giving consideration
to the use of a cough suppressant. Coughing clears the back of
the throat and lower respiratory tract, i.e. the trachea, bronchi
and bronchioles, of secretions and foreign particles. Care should
be taken to only suppress dry, irritating and non-productive
coughs, and only once this has been established as safe and
desirable (Table IV). Coughing that is due to bronchoconstriction
or bronchospasm (which may be found in asthmatic patients, for
example) should be managed with appropriate bronchodilators.
Infections of the lower respiratory tract must be suitably treated
with antimicrobial agents. Drugs that are capable of suppressing
this reex include the opioid analgesics and opioid derivatives,
such as dextromethorphan, pholcodine, codeine phosphate,
methadone and noscapine.
10
Expectorants and mucolytic agents
Expectorants and mucolytic agents are drugs that promote the
coughing up of sputum by decreasing the viscosity of the bronchial
secretions. This may ease a productive cough by making it easier
for the patient to expel the mucus from the lower respiratory tract.
There are two ways of achieving this through pharmacological
intervention:
10
• By using expectorants to increase the volume of bronchial
secretions and produce more uid-like mucus, i.e. increased
secretions with decreased viscosity. Guaiphenesin, sodium
Table III: Priority individuals who require vaccination against the
inuenza virus
3,7
Condition
Pregnant women or those who plan to fall pregnant in the u season
People with underlying medical conditions, such as chronic lung disease,
including asthma, COPD, heart disease, sickle cell anaemia, diabetes,
chronic liver disease and other chronic conditions
People aged 18 years and younger on chronic aspirin therapy
HIV-infected persons with a CD4 count above 100 cells/µl
People diagnosed with cancer and other conditions that might lead to a
weakened immune system
People on long-term steroid treatment for any condition
Everyone who is older than 65 years of age
Front-line healthcare workers who have direct contact with patients
Children aged 6-49 months of age
People staying in old age homes, chronic care facilities and rehabilitation
institutions
COPD: chronic obstructive pulmonary disease, HIV: human immunodeciency virus

2014 Vol 81 No 6S Afr Pharm J 23
ReView
Table IV: Over-the-counter medication for the common cold and u
Over-the-counter medication
Preparation Active ingredients Indications Price
Topical decongestants
Illiadin
®
Oxymetazoline (0.100 mg/ml) Short-term symptomatic relief of nasal congestion R31.90
Drixine
®
Oxymetazoline (0.5 mg/ml) Short-term symptomatic relief of nasal congestion R32.26
Nazene
®
Adult Nasal
Metered Spray
Oxymetazoline (0.5 mg/ml) Short-term symptomatic relief of nasal congestion R35.99
Otrivin
®
Xylometazoline (1 mg/ml) Short-term symptomatic relief of nasal congestion R53.71
Sinutab
®
Nasal
Spray
Xylometazoline (1 mg/ml) Short-term symptomatic relief of nasal congestion R35.00
Vibrocil-S
®
Phenylephrine and dimethindene
(250 mg/100 g)
Short-term symptomatic relief of nasal congestion R37.19
Topical corticosteroids
Beclate Aquanase
®
Beclomethasone dipropionate (50 µg/spray) Maintenance therapy for allergic rhinitis R55.70
Beconase
®
Beclomethasone dipropionate (50 µg/spray) Maintenance therapy for allergic rhinitis R107.66
Clenil
®
Aq Nasal
Spray
Beclomethasone dipropionate (50 µg/spray) Maintenance therapy for allergic rhinitis R51.35
Flomist
®
Fluticasone propionate (50 µg/spray) Maintenance therapy for allergic rhinitis R73.92
Flonase
®
Fluticasone propionate (50 µg/spray) Maintenance therapy for allergic rhinitis R68.40
Nexomist
®
Mometasone furoate (50 µg) Maintenance therapy for allergic rhinitis R170.74
Rinelon
®
Mometasone furoate (50 µg) Maintenance therapy for allergic therapy R74.81 (60 metered sprays)
R174.57 (140 metered sprays)
Topical antihistamines/antiallergic agents
Rhinolast
®
Azelastine (0.14 mg/spray) Short-term intermittent allergic rhinits R51.30
Sinumax Allergy
Nasal Spray
®
Levocabastine (0.5 mg/ml) Short-term intermittent allergic rhinitis R69.51
Vividrin
®
Cromoglicic acid (2.6 mg/spray) Intermittent or persistant allergic rhinitis R34.58
Other nasal preparations
Mistabron
®
Mesna (50 mg/ml) Nasal obstruction owing to thick secretions R101.97
Systemic nasal decongestants with antihistamines
Actifed
®
Pseudoephedrine HCl (30 mg)
Triprolidine HCl (1.25 mg)
Systemic decongestion of nasal mucosa and
sinuses associated with colds and u
R19.54
Betafed Be-Tabs
®
Pseudoephedrine HCl (30 mg)
Triprolidine HCl(1.25 mg)
Systemic decongestion of nasal mucosa and
sinuses associated with colds and u
R17.05
Demazin Syrup
®
Phenylephrine HCl (2.5 mg/5 ml)
Chlorpheniramine (1.25 mg/5 ml)
Systemic decongestion of nasal mucosa and
sinuses associated with colds and u
R39.52
Demazin NS
®
Pseudoephedrine sulphate (120 mg)
Loratidine (5 mg)
Systemic decongestion of nasal mucosa and
sinuses associated with colds and u
R26.51
Systemic decongestant and/or analgesic and/or antihistamine combinations
Benylin
®
for colds Pseudoephedrine HCl (30 mg)
Ibuprofen (200 mg)
Symptomatic relief of colds and u R41.44
Nurofen
®
Cold and
Flu
Ibuprofen (200 mg)
Pseudoephedrine HCl (30 mg)
Symptomatic relief of colds and u R47.66
Sinuclear
®
Paracetamol (325 mg)
Phenylpropanolamine HCl (18 mg)
Symptomatic relief of colds and u R33.61
Sinugesic
®
Paracetamol (500 mg)
Pseudoephedrine HCl (30 mg)
Symptomatic relief of colds and u R22.54
Sinumax
®
Paracetamol (500 mg)
Pseudoephedrine HCl (30 mg)
Symptomatic relief of colds and u R45.31
Sinustat
®
Paracetamol (325 mg)
Phenylpropanolamine HCl (18 mg)
Symptomatic relief of colds and u R21.16
Sudafed
®
Sinus Pain Paracetamol (500 mg)
Pseudoephedrine HCl (60 mg)
Symptomatic relief of colds and u R14.23

2014 Vol 81 No 6S Afr Pharm J 24
ReView
citrate and ammonium chloride are examples of expectorants.
For obvious reasons, the use of cough mixtures containing an
expectorant, as well as an antitussive agent, or combined with
an antihistamine, should rather be avoided.
10
• By using mucolytic agents, such as carbocisteine, bromhexine
and N-acetylcysteine. These drugs are capable of changing the
structure of the mucus itself, resulting in decreased viscosity.
Dornase alfa (recombinant human DNase) is used in patients
with cystic brosis.
10
Maintaining an optimal hydration status and the use of steam
inhalation also assists in decreasing mucous viscosity.
10
Oral decongestants
Oral decongestants are available in many combination products
that may also contain antihistamines. They should be used for
the short-term only, and as symptomatic relief for acute coryza,
as part of u and inuenza. Topical preparations are preferred as
these reduce systemic side-eects.
3,6,7
The literature states that the
use of combination products that contain oral sympathomimetic
and antihistamines only provided a small marked improvement
in general symptoms, with side-eects that may impair
functioning, e.g. agitation, sedation, dizziness, a dry mouth and
headaches. Systemic decongestants include sympathomimetic
pseudoephedrine, phenylpropanolamine and phenylephrine.
Explicit advice should be given to patients to avoid combinations
of oral decongestants with alcohol and certain drugs, such as
monoamine oxidase inhibitors and other sedatives.
3,6,7
Nasal decongestants
A congested, i.e. a “blocked” or “stuy” nose, is the result of
vasodilatation and oedema of the nasal mucosa, which may
be accompanied by inammation, depending on the cause.
Therefore, vasoconstrictors will alleviate congestion.
10
These
decongestants are alpha-1 adrenergic agonists and may be
applied topically or taken systemically.
10
Anti-inammatory
treatment with topical glucocorticosteroids may also be required,
as well as suitable antihistamines, in the case of allergic rhinitis.
Sodium cromoglycatenasal spray may also be used for the latter.
10
Antiviral agents
Neuraminidase inhibitors
Zanamivir and oseltamivir are currently available. These drugs
are registered for the prophylaxis of the inuenza A and B virus,
Cough preparations
Mucolytic
Solmucol
®
N-Acetylcysteine To reduce viscosity of secretions R93.39 (20 sachets/200 mg)
R161.24 (30 sachets/400 mg)
Mucatak
®
R51.59
(25
effervescent
tablets/200 mg)
Amuco 200
®
R43.77
(20
effervescent
tablets/200 mg)
ACC200
®
R58.86
(25
effervescent
tablets/200 mg)
Betaphlem
®
Carbocisteine To reduce viscosity of secretions R17.93 (250 mg/5 ml, 200 ml)
Bronchette
®
R15.23 (250 mg/5 ml, 200 ml)
Flemex
®
R69.81 (250 mg/5 ml, 200 ml)
Lessmusec
®
R26.01 (375 mg, 30 caps)
Mucospect
®
R24.02 (250 mg/5 ml, 200 ml)
Bisolvon
®
Bromhexine HCl To reduce viscosity of secretions R67. 54 (10 mg/5 ml, 50 ml)
Expectorants
Benylin Wet Cough
Menthol
®
Guaifenesin Cough alleviation R18.70 (200 mg/10 ml, 50 ml)
R27.93 (100 ml)
Cough suppressants
Benylin
®
Dry Cough Dextromethorphan Symptomatic relief of a non-productive cough R32.81 (15 mg/5 ml, 100 ml)
R65.65 (200 ml)
Dilinct
®
Dry Cough R23.13 (15 mg/5 ml, 100 ml)
R46.27 (200 ml)
Nitepax
®
Noscapine R55.89 (25 mg/5 ml, 100 ml)
R111.79 (200 ml)
Pholtex
®
Forte Pholcodine R37.80 (15 mg/5 ml, 100 ml)
Pholtex Linctus
®
Pholcodine 15 mg/10ml
Phenyltoloxamine (10 mg/10 ml)
R40.58 (100 ml)

2014 Vol 81 No 6S Afr Pharm J 26
ReView
and should be used within the rst 24 hours of the onset of the
symptoms. These drugs target and inhibit neuraminidase, an
enzyme involved in viral replication. Both of them have shown
only a modest reduction in illness duration.
Important information regarding the use of these drugs is as
follows:
7,11
• They may be used to treat both inuenza A and B
• The reduction provided in the length of symptoms is only for
approximately one day, and only when started within 48 hours
of the symptoms presenting
• They may reduce transmission of the virus
• Oseltamivir has been approved in preventing the virus from
occurring in patients aged one year and older
• They can be used to prevent the complications of the virus,
but only when used within the rst four days of the condition
presenting
• Their use in avian u has not been fully elucidated and requires
further investigation
• Oseltamivir should be initiated promptly in individuals at high
risk of complications of inuenza and of contracting inuenza,
e.g. pregnant women and immunocompromised patients
• Reports of fatal neuropsychiatric conditions have been led.
Important dierences between oseltamivir and zanamivir are:
7,11
• Zanamivir is administered through an inhaler and may provide
challenges to older patients with regard to administration of the
device, as well as to asthmatic patients and patients with lung
disorders. The drug should only be used in its original inhaler
device
• Oseltamivir is available as a liquid (suspension) and as a capsule
with minor side-eects, e.g. nausea and vomiting. Dosage
adjustments should be made in patients with renal impairment.
N-methyl D-aspartate receptor antagonists
Amantadine is an antiviral drug that is used to prevent and treat
inuenza A, but which can also be utilised in the treatment and
management of Parkinson’s disease. Amantidine increases the
release of dopamine from the nigrostriatal neurons. It also inhibits
the reuptake of dopamine by the neurons.
12
Only a minority
of strains is still sensitive to amantadine, and it is currently not
recommended for treatment or use as an antiviral agent.
If there is still sensitivity to the drug, the following is applicable.
3
• It should be initiated within two days of contracting inuenza
A. It may shorten the duration of the disease and reduce its
severity
• It is not eective against inuenza B
• It has not been proved to prevent complications of inuenza,
e.g. pneumonia and bronchitis.
Conclusion
Antibiotics should not be used to treat a common cold or the u.
There is also not enough evidence to support the use of OTC drugs
in the prevention thereof. Receiving an inuenza vaccine may
reduce the likelihood of acquiring seasonal inuenza. Treatment
is aimed at alleviating symptoms. However, many OTC medicines
are not supported by evidence in the scientic literature. Herbal
remedies may be eective, and include P. sidoides extract, A.
paniculataand elderberry. The use of codeine and antihistamines
as monotherapy is not eective in the management of coughs
or other cold symptoms. Medications, such as paracetamol and
other NSAIDs, may be used to manage pain and fever in adults.
Antivirals, especially the neuraminidase inhibitors, can be utilised
to treat and prevent inuenza A and B, but should be used within
two days of the correct diagnosis having been made. Large-scale
resistance to amantadine by inuenza has limited its usefulness.
References
1. NHS National Prescribing Centre. Common cold. NHS [homepage on the Internet]. 2006.
c2014. Available from: http://www.npc.nhs.uk/merec/infect/commonintro/resources/
merec_bulletin_vol17_no3_common_cold.pdf
2. Rutter P. Community pharmacy. 2nd ed. London: Elsevier; 2009
3. Simon H, Zieve D. Colds and u: an in-depth report on the diagnosis, treatment and pre-
vention of colds and u. University of Maryland Medical Centre [homepage on the Inter-
net]. 2013. c2014. Available from: http://health/medical/reports/articles/colds-and-the-u
4. Hermsen ED, Rupp ME. Inuenza. Pharmacotherapy: a pathophysiologic approach. In: DiP-
iro JT, editor.New York: McGraw Hill, 2008; p.1791-1799.
5. Ebell MH, Alfonso A. A systematic review of clinical decision rules for the diagnosis of inu-
enza. Ann Fam Med. 2011:9(1):69-77.
6. Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician.
2007;75(4):515-520.
7. Rossiter D, editor. South African medicines formulary. 11th ed. Cape Town: Health and
Medical Publishing Group; 2014.
8. Guppy MPB, Mickan SM, Del Mar CB. “Drink plenty of uids”: a systematic review of evi-
dence for this recommendation in acute respiratory infections. BMJ. 2004328(7438):499-
500.
9. Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am
Fam Physician. 2012;86(2):153-159.
10. Schellack G, editor). Pharmacology in clinical practice: application made easy for nurses
and allied health professionals. 2nd ed. Claremont: Juta and Company; 2010.
11. Jeerson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treat-
ing inuenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106.
12. Brenner GM, Stevens CW. Pharmacology. 3rd ed. Philadelphia: Saunders and Elsevier; 2010.
13. Snyman JR, editor. Monthly index of medical specialities. Cape Town: Magazine Publishers
Association of South Africa; 2014;53(11).